This study was designed to investigate the mediator(s) of endothelium-dependent arterial constrictor responses evoked by arachidonic acid in vitro. A segment of descending rabbit thoracic aorta was isolated and perfused (1-2 mUmin) with oxygenated Krebs' bicarbonate buffer. Changes in the vascular smooth muscle-contracting activity of the aortic effluent were detected by superfusion bioassay using either strips of rabbit aorta or rings of dog saphenous vein, both denuded of endothelium and exposed to indomethacin (10 1M). Arachidonic acid (5-50 ,ug) injected into the inflow of the perfused aorta caused a dose-related increase in the vascular smooth muscle-contracting activity of the aortic effluent, whereas arachidonic acid added directly into the aortic effluent did not. The arachidonic acid-induced elevation of vascular smooth muscle-contracting activity in the aortic effluent was not apparent when indomethacin (10 ,M) was added to the aortic inflow to inhibit cyclooxygenase, when the endothelium of the perfused aorta was removed by rubbing, or when the thromboxane AJprostaglandin H2 receptors of the vascular tissues used for bioassay were blocked with an antagonist (1 ,uM SQ29548), and was unaffected when an inhibitor of thromboxane synthase (10 ,uM CGS 13080) was added to the aortic inflow. This effect of arachidonic acid was accompanied by release of prostaglandin H2 (measured as prostaglandin F2, after reduction with SnCI2) in amounts sufficient to elicit contraction of the vascular tissues used for bioassay and was attenuated when a reducing agent (2 mM FeCI2) that converts prostaglandin H2 to 12-heptadecatrienoic acid was added to the aortic effluent. Collectively, these observations suggest that arachidonic acid stimulates endothelium-dependent release from the perfused aorta of a prostanoid that contracts vascular smooth muscle via interaction with thromboxane AJprostaglandin H2 receptors. The study also suggests that the prostanoid responsible for the vascular smooth muscle-contracting activity of the aortic effluent is a prostaglandin endoperoxide(s) rather than thromboxane A2. (Circulation Research 1991;69:396-405) R emoval of the endothelium decreases in varying degrees the constrictor response of isolated blood vessels to hypoxia,1 to rapid stretch,2 and to several substances including acetylcholine, calcium ionophore A23187, norepinephrine, and arachidonic acid,3-5 implying that the vasoconstrictor effects of these stimuli are endothelium dependent. Vasoconstrictor events that are endothe- Received May 22, 1990; accepted April 16, 1991. lium dependent may be mediated by one or more endothelium-derived constrictor factors including endothelin,6 certain oxygen-derived free radicals,7 and metabolites of arachidonic acid.8,9
This study was designed to investigate the mediator(s) of endothelium-dependent arterial constrictor responses evoked by arachidonic acid in vitro. A segment of descending rabbit thoracic aorta was isolated and perfused (1-2 mUmin) with oxygenated Krebs' bicarbonate buffer. Changes in the vascular smooth muscle-contracting activity of the aortic effluent were detected by superfusion bioassay using either strips of rabbit aorta or rings of dog saphenous vein, both denuded of endothelium and exposed to indomethacin (10 1M) . Arachidonic acid (5-50 ,ug) injected into the inflow of the perfused aorta caused a dose-related increase in the vascular smooth muscle-contracting activity of the aortic effluent, whereas arachidonic acid added directly into the aortic effluent did not. The arachidonic acid-induced elevation of vascular smooth muscle-contracting activity in the aortic effluent was not apparent when indomethacin (10 ,M) was added to the aortic inflow to inhibit cyclooxygenase, when the endothelium of the perfused aorta was removed by rubbing, or when the thromboxane AJprostaglandin H2 receptors of the vascular tissues used for bioassay were blocked with an antagonist (1 ,uM SQ29548), and was unaffected when an inhibitor of thromboxane synthase (10 ,uM CGS 13080) was added to the aortic inflow. This effect of arachidonic acid was accompanied by release of prostaglandin H2 (measured as prostaglandin F2, after reduction with SnCI2) in amounts sufficient to elicit contraction of the vascular tissues used for bioassay and was attenuated when a reducing agent (2 mM FeCI2) that converts prostaglandin H2 to 12-heptadecatrienoic acid was added to the aortic effluent. Collectively, these observations suggest that arachidonic acid stimulates endothelium-dependent release from the perfused aorta of a prostanoid that contracts vascular smooth muscle via interaction with thromboxane AJprostaglandin H2 receptors. The study also suggests that the prostanoid responsible for the vascular smooth muscle-contracting activity of the aortic effluent is a prostaglandin endoperoxide(s) rather than thromboxane A2. (Circulation Research 1991;69:396-405) R emoval of the endothelium decreases in varying degrees the constrictor response of isolated blood vessels to hypoxia,1 to rapid stretch,2 and to several substances including acetylcholine, calcium ionophore A23187, norepinephrine, and arachidonic acid,3-5 implying that the vasoconstrictor effects of these stimuli are endothelium dependent. Vasoconstrictor events that are endothe-lium dependent may be mediated by one or more endothelium-derived constrictor factors including endothelin,6 certain oxygen-derived free radicals,7 and metabolites of arachidonic acid. 8, 9 That metabolites of arachidonic acid by cyclooxygenase contribute to endothelium-dependent vasoconstrictor responses is suggested by reports that inhibitors of cyclooxygenase attenuate many such responses. For example, cyclooxygenase inhibitors were shown to inhibit constrictor responses to arachidonic acid in rabbit aortas8 and in canine cerebral arteries3 and systemic veins.9 Cyclooxygenase inhibitors were also found to reduce constrictor responses to calcium ionophore A23187, acetylcholine, norepinephrine, and stretch in canine basilar arteries2,3 and responses to acetylcholine in rabbit intrapulmonary arteries10 and the aortas of spontaneously hypertensive rats. ' Figure 1 shows that both the superfused strips of rabbit aorta and rings of canine saphenous vein contracted when exposed to authentic PGH2 (1 ng) and U46619 (1 ng), a synthetic agonist for the TXAJPGH2 receptor, but were virtually unresponsive to PGI2 (50-100 ng), PGE2 (100 ng), and PGF2a (50-100 ng) at the stipulated doses.
The experiments were initiated by ascertaining that the vascular tissues used for bioassay were appropriately responsive to U46619 injected as a bolus into the effluent of the perfused aorta. Subsequently, arachidonic acid was injected as a bolus into the inflow or the effluent of the perfused aorta, and the response of the strip of rabbit aorta or ring of canine saphenous vein used for bioassay of contracting activity in the effluent was recorded. The purpose of assaying the vascular smooth muscle-contracting activity of the aortic effluent on two vascular preparations was to obtain estimates of such an activity in independent assay systems that are mutually verifiable. When so indicated, to quantify the arachidonic acid-induced increments of vascular smooth musclecontracting activity in the aortic effluent, the response of assay tissues to arachidonic acid was bracketed between responses in the same assay tissue to two or more injections into the aortic effluent of a reference standard, at varying doses that elicit logdose-related submaximal contractile responses that are both larger and smaller than the response elicited by arachidonic acid. Other investigators16 have used a similar approach to quantify by bioassay the release of TXA2-like materials from isolated perfused organs. In four experiments, the standard of reference used for bioassay of vascular smooth muscle-contracting activity was U46619, a stable analogue of PGH2, which specifically activates TXA2/PGH2 receptors. 12 In four other experiments, the arachidonic acid-induced elevation of vascular smooth musclecontracting activity in the aortic effluent was assayed on rings of canine saphenous veins using authentic PGH2 as the standard of reference. Estimates of vascular smooth muscle-contracting activity in the aortic effluent are expressed as picomole equivalents of the appropriate reference standards, U46619 or PGH2, per unit luminal surface area of perfused aorta. When indicated, the contracting activity of the aortic effluent, measured and expressed as stated above, was multiplied by the surface area of the perfused aorta to obtain estimates of the vascular smooth muscle-contracting activity released from each perfused aorta.
The effect of arachidonic acid on release of vascular smooth muscle-contracting material from the perfused rabbit aorta was studied in preparations with and without endothelium. The endothelium of the perfused aorta was removed by gentle rubbing around polyethylene tubing; the aorta was then flushed with Krebs' bicarbonate buffer and reattached to the perfusion system. The effect of arachidonic acid on release of vascular smooth musclecontracting material also was studied in the presence and the absence of indomethacin (10 ,uM) or CGS 13080 (10 ,uM) , added to the inflow of the perfused concentrations as high as 10`M. The role of TXAJ PGH2 receptors in the implementation of the vascular smooth muscle contraction elicited by material released from the perfused aorta by arachidonic acid was investigated by comparing the responses obtained in the presence and the absence of SQ29548 (1 ,M), added to the effluent of the perfused aorta to block TXA2/PGH2 receptors in the vascular tissues used for bioassay. 20 In complementary experiments, to study the biological stability of the vascular smooth muscle-contracting material(s) released from the perfused rabbit aorta in response to arachidonic acid, the aortic effluent (2.5 ml) was collected over a 2.5-minute period extending from minute 2.0 to minute 4.5 after injection of a 50 -,ug bolus of arachidonic acid into the aortic inflow. The 2.0-minute interval separating the injection of arachidonic acid from the onset of sample collection corresponds approximately to the interval separating the injection of the fatty acid from the appearance of smooth muscle-contracting activity in the aortic effluent. Immediately after completion of the collection, aliquots (100 ,u1) of aortic effluent maintained at 37°C were tested at 4-minute intervals for contracting activity on rings of canine saphenous veins superfused with Krebs' bicarbonate buffer as described above. For the purpose of comparisons, the effluent of perfused aortas that had not been challenged with arachidonic acid was collected for 2 minutes (2 ml), and authentic PGH2 (20 ng) was added to the sample so collected. Immediately thereafter, aliquots (100 pl) of the PGH2-containing sample were tested at 4-minute intervals for contracting activity as indicated above.
Experiments to Study Release of PG Endoperoxides
From the Perfuised Aorta Experiments were conducted to examine whether or not the effluent of descending thoracic aortas perfused as described above contains PG endoperoxides after injection of arachidonic acid into the aortic inflow. Arachidonic acid was injected (5-or 50-,ug bolus) into the inflow of the perfused aorta at two time periods separated by a 30-minute interval. After each injection, 2.0 minutes was allowed to elapse before the aortic effluent was collected for 2.5 consecutive minutes. Randomly, one collection was made into 25 ml ethanol containing SnCl2 (5 mg/ml, pH 2.3), and another collection was made into 25 2.0-2.5 minutes, arachidonic acid injected into the aortic inflow elicited contraction of the strips of rabbit aorta (Figures 2A-2E ) and rings of canine saphenous vein ( Figure 3A-3D) , whereas arachidonic acid injected into the aortic effluent had little or no effect (Figures 2A, 2C, 3A, 3B, and 3D) . Hence Figures 2C and 3C) , was abolished by SQ29548 (1 gM) added to the aortic effluent to block the TXA2/PGH2 receptors of the strips of aorta and rings of saphenous vein used for bioassay ( Figures 2D and 3D) , and was greatly attenuated by FeCl2 (2 mM) added to the aortic effluent to reduce the PG endoperoxides to 12-HHT ( Figure 2E) . A synthetic agonist for TXA2/PGH2 receptors, U46619, also elicited contraction of the aortic strips used for bioassay when injected into the effluent of the perfused aorta; this effect of U46619 was blocked by addition to the aortic effluent of SQ29548 but not of FeCl2 ( Figures 2D and 2E ). SQ29548 also blocked the contraction of canine saphenous vein elicited by addition to the aortic effluent of U46619 or authentic PGH2 ( Figure 3D ). As shown in Figure 4A , aortic effluent collected over a 2.5 -minute period, from minute 2.0 to minute 4.5, after injection of a 50-,g bolus of arachidonic acid into a perfused aorta, demonstrated vascular smooth muscle-contracting activity when 100-pl aliquots were bioassayed on rings of canine saphenous vein superfused with Krebs' bicarbonate buffer. Contracting activity was maximal in aliquots of aortic effluent assayed immediately after completion of sample collection (0 minutes) but declined greatly in aliquots taken from samples of effluent kept at 37°C for 4-8 minutes, suggesting that the material(s) responsible for the musculotropic activity of the aortic effluent is labile. A similar loss of vascular smooth muscle-contracting activity as a function of time at 37°C was noted in samples obtained by mixing authentic PGH2 and the effluent of a perfused aorta not challenged with arachidonic acid ( Figure 4B ). Before mixing with PGH2, vascular smooth musclecontracting activity was not detected in the effluent of perfused aortas not challenged with arachidonic acid (data not shown).
Shown in Figure 5 , release of vascular smooth muscle-contracting material from the perfused rabbit aorta was quantified independently by bioassay on superfused strips of rabbit aorta and rings of canine saphenous vein using U46619 as the standard of reference. Both bioassay tissues yielded similar estimates of contracting material release, which was found to increase as a function of the amount of arachidonic acid injected. Release of vascular smooth muscle-contracting material from the perfused rabbit aorta also was quantified by bioassay on superfused rings of canine saphenous vein using authentic PGH2 as the standard of reference. In four experiments, arachidonic acid injected as a 5-and 50 -,g bolus into the perfused rabbit aorta elicited release of 0.14+0.06 and 1.30+0.17 pmol PGH2 equivalents/ fused with Krebs' bicarbonate buffer containing 10 pM indomethacin) to direct injection over the rings ofaliquots (100 pl) of samples obtained as follows: In panel A, the aliquots injected were derivedfrom a sample ofaortic effluent collected over a 25-minute period after a 50-pg bolus injection of arachidonic acid into a perfused aorta. In panel B, the aliquots were derived from a sample prepared by mixing 20 ng authentic prostaglandin H2 and a 2-minute collection (2 ml) of effluent of a perfused aorta that had not been challenged with arachidonic acid. Samples so obtained were maintained at 37°C and were tested at 4-minute intervals for vascular smooth muscle-contracting activity starting immediately (0 minutes) after completion ofsample collection (panelA) or of sample preparation (panel B).
cm2 luminal surface area, respectively, which corresponds to 0.33±0.14 and 2.82±0.37 ng PGH2 equivalents released per aorta.
Release of Prostanoids From the Perfused Aorta Figure 6 depicts measurements of prostanoids released from perfused rabbit aortas over a 2.5-minute period, from minute 2.0 to minute 4.5, after injections of 5-and 50-,ug bolus doses of arachidonic acid. Aortic effluents, collected in both the presence and absence of SnCl2, which is known to reduce PG endoperoxides to PGF2a, contained, in decreasing order, PGI2 (measured as 6-keto-PGFil), PGE2, (Figure  7 ). This effect of arachidonic acid was not expressed (p<0.001) in aortic rings denuded of endothelium or in rings bathed in media containing either aspirin (500 1,M) or indomethacin (10 ,uM) (p<0.001) to inhibit cyclooxygenase (Figure 7) . The arachidonic acid-induced contraction of rabbit aortic rings was not affected by addition to the bathing media of CGS 13080 (10 ,tM) to inhibit TX synthase but was greatly attenuated by the TXA2/PGH2 antagonists SQ29548 (1 ,uM) (p<0.001) and BM 13.177 (10 ,uM) (p<0.001) (Figure 7 ).
Discussion
The central finding of this study is that arachidonic acid elicits release from the isolated perfused rabbit aorta of material(s) that causes contraction of superfused rings of canine saphenous veins and strips of rabbit aorta. Several complementary findings offer insights into the nature of this effect of arachidonic acid. First, the fatty acid does not release vascular smooth muscle-contracting material(s) from perfused aortas that either are denuded of endothelium or are exposed to buffer containing indomethacin to inhibit cyclooxygenase. Second, the vasoactive material released from the perfused aorta by arachidonic acid does not cause contraction of vascular preparations superfused with buffer containing SQ29548 to block TXAJPGH2 receptors. Collectively, these observations suggest that the material(s) released by WITHOUr 6-keto-PGF&Jng) 7 6 5 4 Arochidonic Acid (-log M) ' 27 the PGI2-induced contraction of isolated rat and rabbit aorta is endothelium dependent and is mediated by a constrictor prostanoid. In our study, the approximate amount of PG12 (31.4 ng/aorta), PGE2 (5.5 ng/aorta), or PGF2a (1.6 ng/ aorta) released from perfused aortas after a challenge with 50 ,ug arachidonic acid is below that required by each prostanoid to elicit contraction of the superfused vascular tissues used for bioassay of vasoconstrictor activity in the aortic perfusate (see Figure 1) . Hence, it is unlikely that either PGI2, PGE2, or PGF2a contributes significantly to the vascular smooth muscle-contracting activity that is released from the perfused aorta by arachidonic acid.
The possibility that TXA2 contributes to the vascular smooth muscle-contracting activity released by arachidonic acid from the perfused aorta is disputable, because in the present study such a release was unaffected by the TX synthase inhibitor CGS 13080. However, it can be argued that reductions of TXA2 release after inhibition of TX synthase, if accompanied by attendant elevations of PG endoperoxide release, need not necessarily result in diminished vasoconstrictor activity in the aortic effluent. Relevant to this point, it is known that PG endoperoxides and TXA2 share receptors that can be blocked by SQ29548 and that, when activated, result in contraction of vascular smooth muscle. 12 According to this study in perfused rabbit aortas, there is general agreement between estimates of 5-and 50-,ug arachidonic acid-induced release of PG endoperoxides (0.35 and 1.96 ng/aorta, respectively), measured as PGF2a, and estimates of 5-and 50 -,g arachidonic acid-induced release of canine saphenous vein-contracting material determined by bioassay using PGH2 as a standard (0.33 and 2.82 ng/aorta, respectively). The notion that PG endoperoxides contribute to the vascular smooth muscle-contracting activity released by arachidonic acid from the perfused aorta is additionally supported by the finding that the expression of such contracting activity is reduced by the addition of FeCl2 to the aortic effluent superfusing a strip of rabbit aorta used for assay of vasoactivity. FeCl2 is presumed to diminish the concentration of PG endoperoxides in the aortic effluent, as it promotes their reduction to 12-HHT,19 a substance that is without aortic muscle-contracting activity. According to a recent report,28 the endothelium-dependent contraction of aortic smooth muscle caused by 20-hydroxyeicosatetraenoic acid also appears to be mediated by the corresponding PG endoperoxides that are generated by cyclooxygenase.
From the preceding discussion, PG endoperoxides emerge as the most likely constituents of the vascular smooth muscle-contracting material that is released in an endothelium-dependent manner from the perfused rabbit aorta in response to a challenge with arachidonic acid. PG endoperoxides also may contribute to the mechanism of arachidonic acid-induced contraction of rings of rabbit aorta. 8 This effect of arachidonic acid exhibits dependence on both the endothelium and cyclooxygenase activity8 and, as demonstrated by the present study, is attenuated by blockers of TXAJPGH2 receptors but not by an inhibitor of TX synthase. Blockers of TXAJ PGH2 receptors also were reported to attenuate the expression of acetylcholine-induced contraction of aortic rings from spontaneously hypertensive rats,29 to inhibit the vasoconstrictor effect of arachidonic acid in the isolated perfused rat kidney,14 and to lower blood pressure and produce renal vasodilation in rats with established angiotensin Il-salt-induced hypertension.30 '31 In none of these experimental models could the response to blockers of TXAJ PGH2 receptors be mimicked by inhibitors of TX synthase.14,29-31 This raises the possibility that the reported effects of the TXAJPGH2 receptor blockers reflect interference with the vasoconstrictor actions of a prostanoid other than TXA2. Whether or not PG endoperoxides are such prostanoids is yet to be established.
In summary, the present study demonstrates that arachidonic acid elicits endothelium-dependent release from the isolated perfused rabbit aorta of a prostanoid(s) that interacts with TXA2/PGH2 receptors to cause contraction of vascular smooth muscle. The study also suggests that a PG endoperoxide that contracts vascular smooth muscle and is released from the perfused aorta by arachidonic acid can be such a prostanoid.
